<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04223531</url>
  </required_header>
  <id_info>
    <org_study_id>191254</org_study_id>
    <nct_id>NCT04223531</nct_id>
  </id_info>
  <brief_title>The Natriuretic Peptide Response to Saline Infusion</brief_title>
  <official_title>The Natriuretic Peptide Response to Saline Infusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate the overarching hypothesis that obese and black
      individuals have relatively lower circulating natriuretic peptide levels compared with lean
      and white individuals. Conventional clinical assays for measurement of circulating
      natriuretic peptides display substantial overlap, precluding determination of the basis of
      the relative natriuretic peptide deficiency previously observed in these groups. We will
      study lean or obese, black or white, healthy adult subjects with intravenous (IV) saline
      infusion as a stimulus for natriuretic peptide production and release. We will measure
      circulating levels of natriuretic peptide isoforms using mass spectrometry that allows the
      specific identification of proBNP 1-108 and its cleavage product BNP 1-32.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in circulating levels of proBNP 1-108 from baseline to 6 hours</measure>
    <time_frame>Saline infusion will be given for 2 hours (with 4 hour observation) with blood samples collected at hourly intervals for 7 hours total</time_frame>
    <description>proBNP 1-108 is a protein made by the heart. The change in circulating levels will be measured in response to saline infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in circulating levels of proBNP 1-32 from baseline to 6 hours</measure>
    <time_frame>Saline infusion will be given for 2 hours (with 4 hour observation) with blood samples collected at hourly intervals for 7 hours total</time_frame>
    <description>BNP 1-32 is a hormone made by the heart. The change in circulating levels will be measured in response to saline infusion</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Each participant will receive a saline infusion of normal saline 0.9%NaCl</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline 0.9% Infusion Solution Bag</intervention_name>
    <description>Participants will receive a normal saline infusion at a rate of 10ml per unit of body surface area per minute for 120 minutes.</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 65 years;

          -  BMI between 18 and 25 (lean) or 30 and 40 kg/m2 (obese);

          -  self-reported race of either black or white;

          -  otherwise healthy with no chronic comorbidities.

        Exclusion Criteria:

          -  History of diabetes mellitus

          -  Currently pregnant

          -  History of cardiac disorder including heart failure, cardiomyopathy, myocardial
             infarction, coronary revascularization, abnormal stress test, uncontrolled arrhythmia
             or arrhythmia requiring treatment, congenital heart disease, pericardial disease.

          -  History of hypertension defined as taking anti-hypertensive medications or untreated
             hypertension with systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90
             mm Hg at most recent clinical visit or screening visit.

          -  Obstructive lung disease

          -  History of chronic kidney disease

          -  History of liver disease or cirrhosis

          -  Uncontrolled thyroid dysfunction

          -  History of solid organ transplant

          -  History of malignancy other than basal or squamous cell skin cancer

          -  Inability to lie flat for 6 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deepak K Gupta, MD, MSCI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deepak K Gupta, MD, MSCI</last_name>
    <phone>6159362530</phone>
    <phone_ext>6159362530</phone_ext>
    <email>d.gupta@vumc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cassandra F Reynolds, BS</last_name>
    <phone>6158759854</phone>
    <phone_ext>6158759854</phone_ext>
    <email>cassandra.f.reynolds@vumc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vanderbilt Univeristy</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Deepak Gupta, MD</last_name>
      <phone>615-936-2530</phone>
      <email>d.gupta@vumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Cassandra F Reynolds, BS</last_name>
      <phone>615-875-9854</phone>
      <phone_ext>6158759854</phone_ext>
      <email>cassandra.f.reynolds@vumc.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 16, 2019</study_first_submitted>
  <study_first_submitted_qc>January 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2020</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Deepak Gupta</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Only deidentified individual participant data will be provided to interested researchers with a data use agreement and confirmation that no protected health information will be shared, all data will be stored in password protected databases accessible to only key study personnel, and that data will be returned or destroyed after completion or 6 years, whichever is shorter.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>No later than 1 year after completion of the study.</ipd_time_frame>
    <ipd_access_criteria>Only deidentified individual participant data will be provided to interested researchers with a data use agreement and confirmation that no protected health information will be shared, all data will be stored in password protected databases accessible to only key study personnel, and that data will be returned or destroyed after completion or 6 years, whichever is shorter.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

